<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Stroke</journal-id><journal-id journal-id-type="iso-abbrev">Stroke</journal-id><journal-id journal-id-type="publisher-id">STR</journal-id><journal-title-group><journal-title>Stroke</journal-title></journal-title-group><issn pub-type="ppub">0039-2499</issn><issn pub-type="epub">1524-4628</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40171654</article-id><article-id pub-id-type="pmc">PMC12101888</article-id>
<article-id pub-id-type="publisher-id">STROKE-2025-050848D</article-id><article-id pub-id-type="art-access-id">00025</article-id><article-id pub-id-type="doi">10.1161/STROKEAHA.125.050848</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>10053</subject><subject>10155</subject><subject>10173</subject><subject>10178</subject></subj-group><subj-group subj-group-type="heading"><subject>Brief Reports</subject></subj-group></article-categories><title-group><article-title>Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6349-5117</contrib-id><name><surname>Roberts</surname><given-names>Lucy</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5865-9495</contrib-id><name><surname>Coutts</surname><given-names>Graham</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5018-2111</contrib-id><name><surname>Dickie</surname><given-names>Ben R.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9078-9919</contrib-id><name><surname>Smith</surname><given-names>Craig J.</given-names></name><degrees>MD</degrees><email>craig.smith-2@manchester.ac.uk</email><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9141-3438</contrib-id><name><surname>South</surname><given-names>Kieron</given-names></name><degrees>PhD</degrees><email>kieron.south@manchester.ac.uk</email><xref rid="fn01" ref-type="fn">*</xref><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9646-4456</contrib-id><name><surname>Allan</surname><given-names>Stuart M.</given-names></name><degrees>PhD</degrees><xref rid="fn01" ref-type="fn">*</xref><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><aff id="aff1">Division of Neuroscience, School of Biological Sciences (L.R., G.C., K.S., S.M.A.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.</aff><aff id="aff2">Division of Informatics, Imaging and Data Sciences, School of Health Sciences (B.R.D.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.</aff><aff id="aff3">Division of Cardiovascular Sciences, School of Medical Sciences (C.J.S.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.</aff><aff id="aff4">Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, The University of Manchester, United Kingdom (L.R., G.C., B.R.D., C.J.S., K.S., S.M.A.).</aff><aff id="aff5">Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, United Kingdom (C.J.S.).</aff></contrib-group><author-notes><corresp id="c1">Correspondence to: Lucy Roberts, PhD, Division of Neuroscience, Faculty of Biology, Medicine and Health, School of Biological Sciences, Manchester Academic Health Science Centre, The University of Manchester, AV Hill Bldg, Upper Brook St, Manchester M13 9PT, United Kingdom. Email <email xlink:href="lucy.roberts@manchester.ac.uk">lucy.roberts@manchester.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2025</year></pub-date><volume>56</volume><issue>6</issue><fpage>1589</fpage><lpage>1595</lpage><history><date date-type="received"><day>17</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>17</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><italic toggle="yes">Stroke</italic> is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="str-56-1589.pdf"/><abstract><sec><title>BACKGROUND:</title><p>r-tPA (recombinant tissue-type plasminogen activator) and its variant, TNK (tenecteplase), are the currently approved thrombolytic drugs for the treatment of acute ischemic stroke, but they are ineffective in a proportion of patients due to r-tPA resistance of platelet-rich thrombi. A novel thrombolytic, caADAMTS13 (constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) has been shown to improve experimental stroke outcomes where platelet-rich thrombi are present but have not been directly compared with r-tPA or TNK.</p></sec><sec><title>METHODS:</title><p>We conducted a direct comparison of caADAMTS13 versus r-tPA versus TNK versus vehicle control in the ferric chloride&#x02013;mediated distal middle cerebral artery occlusion model in mice, which features platelet and VWF (von Willebrand Factor)&#x02013;rich thrombi that reproduce r-tPA-resistant occlusion. Treatments were administered intravenously 1 hour after ferric chloride application by bolus injection or bolus followed by infusion, as translationally applicable. Laser speckle contrast imaging measured early reperfusion over the hour following treatment, and magnetic resonance imaging measured cerebral blood flow and lesion volume at 24 hours.</p></sec><sec><title>RESULTS:</title><p>Reperfusion 1 hour after treatment was greatest in caADAMTS13-treated animals. Later cerebral blood flow, 24 hours post-treatment, within the stroke-affected hypoperfused area was higher in caADAMTS13 and r-tPA but not TNK-treated mice. Functionally, this led to the absence of an initial behavioral deficit in caADAMTS13-treated mice, alongside a smaller lesion volume at 24 hours and reduced extent of bleeding.</p></sec><sec><title>CONCLUSIONS:</title><p>These findings demonstrate an overall suggestion that caADAMTS13 has improved thrombolytic efficacy, compared with current stroke treatments, against platelet-rich thrombi, for which there is currently an unmet clinical need.</p></sec></abstract><kwd-group><kwd>cardiovascular diseases</kwd><kwd>cerebral hemorrhage</kwd><kwd>fibrinolytic agents</kwd><kwd>ischemic stroke</kwd><kwd>therapeutics</kwd><kwd>thrombolytic therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The therapeutic aim of thrombolysis in acute ischemic stroke (AIS) is the fast and effective removal of thrombi occluding cerebral arteries to achieve reperfusion.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> For many years, the only clinically approved thrombolytic to achieve reperfusion has been r-tPA (recombinant tissue-type plasminogen activator; alteplase). However, r-tPA produces effective recanalization in as few as 10% to 35% of patients, depending on the population and cause studied, and is associated with a significant risk of intracerebral hemorrhage.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> More recently, there has been an increase in recommendations for the use of TNK (tenecteplase) as a thrombolytic for AIS.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> TNK is a r-tPA variant with increased fibrin specificity and increased resistance to inhibition and, thus, has a longer half-life than r-tPA.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> This enables TNK administration as a bolus, as opposed to the administration of r-tPA as a 10% volume bolus followed by 90% volume infusion, and a reduction in the required therapeutic dose. Clinical studies have demonstrated that 0.25-mg/kg TNK has a comparable safety profile to 0.9-mg/kg r-tPA in terms of hemorrhagic transformation events and is at least as effective in terms of reperfusion and functional outcomes.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R9" ref-type="bibr">9</xref></sup> In preclinical AIS, r-tPA and TNK both have similar efficacy<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup> with increased safety of TNK only at early administration.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p><p>The comparable efficacy and shared mechanism of action may suggest that the phenomenon of r-tPA resistance, where r-tPA is ineffective at breaking down altered fibrin and nonfibrinous structural components, may similarly occur with TNK. AIS thrombi are broadly characterized into 2 compositions: red blood cell&#x02013;rich consisting of areas packed with red blood cells within a thin, loose meshwork of fibrin, and platelet-rich consisting of dense fibrin and VWF (von Willebrand Factor) structures that delineate platelet-filled areas.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> It is the loose fibrin meshwork of the red blood cell&#x02013;rich thrombus composition that plasmin derived from r-tPA activation is effective at degrading, while the platelet-rich composition is r-tPA-resistant. The greater the proportion of platelet and VWF components, the greater the r-tPA resistance of thrombi.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p>Several preclinical studies have investigated targeting VWF as an alternative thrombolytic strategy, including utilizing the endogenous VWF regulator, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). Targeting the VWF/ADAMTS13 axis is protective in AIS,<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R19" ref-type="bibr">19</xref></sup> but the efficacy of wild-type ADAMTS13 is limited due to its conformational quiescence.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> Inducing point mutations in the linker 3 region of ADAMTS13 produced a structural mutation that formed caADAMTS13 (constitutively active ADAMTS13), which, in 2 preclinical AIS models, demonstrated an ability to improve cerebral blood flow, reduce lesion volume, reduce platelet and fibrin deposition, and displayed anti-inflammatory properties.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> caADAMTS13 additionally displayed antithromboinflammatory properties in vitro and in vivo by reduction of neutrophil rolling and migration.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> For further preclinical translational development of novel thrombolytics, a head-to-head comparison against established thrombolytics should be conducted.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Therefore, the aim of this study was to perform a direct comparison between the novel AIS thrombolytic, caADAMTS13, the thrombolytics in current clinical practice, r-tPA and TNK, and their respective vehicle controls in a murine model of thromboembolic stroke.</p><sec sec-type="methods"><title>Methods</title><p>The data presented are available from the corresponding author upon reasonable request. Full method descriptions are available in the <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Supplemental Material</ext-link>. Animal procedures were carried out in accordance with the UK Animal Scientific Procedures Act (1986), approved by the local ethical review board (The University of Manchester), and followed ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Supplemental Material</ext-link>).<sup><xref rid="R23" ref-type="bibr">23</xref></sup> Male (31&#x02013;40 g) and (26&#x02013;38 g) female CD1 mice (Charles River, United Kingdom) were used (1:1 ratio within treatment groups). Sample sizes were calculated to allow for adequate statistical power based on previous data using a significance level of &#x003b1;=0.05 with 80% power to detect significant differences. Animals were electronically randomly assigned to the experiment, and treatments were randomized within the sexes, with researchers blinded to treatment. Blinding was maintained throughout experimentation and data analysis. To ensure allocation concealment, sequentially labeled tubes of unidentifiable treatment materials were used post-occlusion, at the time of treatment. While it was not practically feasible to blind allocation to bolus or infusion administration methods, the treatments and respective vehicle controls were visually indistinguishable and included across all administration routes.</p><p>The experimental design overview is presented in Figure <xref rid="F1" ref-type="fig">1</xref>A. An intravenous administration route was established by a tail vein catheter. Ferric chloride (FeCl<sub>3</sub>)&#x02013;mediated distal middle cerebral artery occlusion (dMCAo), which forms platelet and VWF-rich, r-tPA-resistant thrombi, was performed using previously described surgical techniques,<sup><xref rid="R24" ref-type="bibr">24</xref></sup> performed under inhaled isoflurane (1.5%&#x02013;2.5% in 30%/70% O<sub>2</sub>/NO<sub>2</sub>) with temperature controlled using a feedback heating pad (37&#x02005;&#x000b0;C&#x000b1;0.5&#x02005;&#x000b0;C). Two rounds of 5-minute, 20% (w/v) FeCl<sub>3</sub> applications were conducted, with saline wash between. A priori exclusions pre-treatment included MCA damage, failure to establish a viable tail vein administration route, and insufficient reduction in cerebral reperfusion based on baseline laser speckle contrast imaging.</p><fig position="float" id="F1"><label>Figure 1.</label><caption><p><bold>Improvement of cerebral blood flow to the stroke-affected area at both 1 and 24 hours following caADAMTS13 (constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) administration. A</bold>, Acute ischemic stroke was induced by topical ferric chloride application on the middle cerebral artery (MCA), and treatments were administered starting 1 hour poststroke induction and laser speckle contrast imaging (LSCI) conducted at 1-minute intervals for 5 minutes pre-treatment and 1 hour post-treatment. Behavior (28-point neuroscore) was conducted at baseline (0 hour), 24 hours, and 48 hours poststroke. Magnetic resonance imaging (MRI) was conducted at 24 hours poststroke with arterial sin labeling MRI to determine cerebral blood flow and high-spatial-resolution T2-weighted MRI to quantify lesion volume. <bold>B</bold>, Representative LSCI of reperfusion from each treatment group at baseline pre-injection and 60 min after treatment injection. Regions of interest for quantification over the ipsilateral and contralateral hemispheres are indicated (black, dashed rectangles). <bold>C</bold>, Ratios of the ipsilateral to contralateral hemisphere flux values were calculated, and the percentage flux ratio between the baseline values pre-treatment and 60 minutes post-treatment was determined (combined sex, n=22&#x02013;24; male, n=11&#x02013;12; and female, n=11&#x02013;12). <bold>D</bold>, Representative MRI arterial spin labeling images from an animal in each treatment group for quantification of cerebral blood flow (CBF). <bold>E</bold>, Ratios of the CBF within the hypoperfused (stroke) area in the ipsilateral hemisphere to the CBF within the whole of the contralateral hemisphere were calculated for individual animals (combined sex, n=19&#x02013;22; male, n=10&#x02013;11; and female, n=9&#x02013;11). Error bars represent mean&#x000b1;SD. Statistics were performed using a 1-way ANOVA followed by (<bold>C</bold>) the Tukey and (<bold>E</bold>) Dunn multiple comparisons post hoc tests. *<italic toggle="yes">P</italic>&#x0003c;0.05; **<italic toggle="yes">P</italic>&#x0003c;0.01. FeCl<sub>3</sub> indicates ferric chloride; caAD13, caADAMTS13; r-tPA, recombinant tissue-type plasminogen activator; TNK, tenecteplase; and Veh, vehicle control.</p></caption><graphic xlink:href="str-56-1589-g001" position="float"/></fig><p>Laser speckle contrast imaging, the primary outcome measure for cerebral reperfusion, was performed every 1 minute, for 5 minutes pre-injection, and 1 hour post-injection as previously described.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Treatments were administered by intravenous tail vein injection, starting at 1 hour post-FeCl<sub>3</sub> application. caADAMTS13 (6 mg/kg),<sup><xref rid="R21" ref-type="bibr">21</xref></sup> TNK (2.5 mg/kg),<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and their respective vehicle controls were administered as a bolus. r-tPA (10 mg/kg)<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> and its respective vehicle control were administered as a 10% volume bolus followed by a 90% volume infusion over 40 minutes. A priori exclusions post-treatment included failure to administer full treatment volume and failure to recover to an acceptable condition.</p><p>Neurological deficits were assessed using a 28-point neuroscore<sup><xref rid="R25" ref-type="bibr">25</xref></sup> at baseline, 24 hours, and 48 hours post-surgery. Twenty-four hours after treatment, arterial spin labeling magnetic resonance imaging (MRI) was used to assess cerebral blood flow, and high-spatial-resolution T2-weighted MRI was used to assess lesion volume. MRI was performed under inhaled isoflurane (1.5%&#x02013;2%), and the core temperature was maintained at 37&#x02005;&#x000b0;C with a feedback-controlled fan heater and rectal probe. Detailed MRI sequence methods can be found in the <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Supplemental Material</ext-link>. Cryopreserved, 10-&#x000b5;m coronal brain sections, sampled at 500-&#x000b5;m intervals throughout the brain, were stained with hematoxylin and eosin for quantification of hemorrhagic transformation with all stained sections considered for hemorrhage quantification. Data are presented as mean&#x000b1;SD. For statistical comparisons, groups were tested for normality, and all groups were compared with each other.</p></sec><sec sec-type="results"><title>Results</title><p>There were no differences between the treatment groups&#x02019; respective vehicle controls; consequently, vehicle treatments were considered as a single group. No significant sex differences were identified throughout the study; therefore, mixed-sex groups were investigated. All treated animals were included in each measurement, except in the case of mortality (5 animals), including due to anesthesia, not recovering to an acceptable condition or displaying severe stroke symptoms<sup><xref rid="R26" ref-type="bibr">26</xref></sup> (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Figure S1</ext-link>), or where technical difficulties arose leading to uncollected data.</p><p>Early reperfusion, measured by the increase in ipsilateral:contralateral ratio laser speckle contrast imaging perfusion 1 hour after thrombolysis, was 2.1-fold greater (<italic toggle="yes">P</italic>=0.006) with caADAMTS13 treatment than vehicle control. Early reperfusion by laser speckle contrast imaging in the caADAMTS13 treatment group was additionally 1.8-fold greater (<italic toggle="yes">P</italic>=0.031) than TNK and 1.6-fold greater (<italic toggle="yes">P</italic>=0.065) than r-tPA. Comparisons between the vehicle control, r-tPA, and TNK groups were not significantly different (Figure <xref rid="F1" ref-type="fig">1</xref>B and <xref rid="F1" ref-type="fig">1</xref>C; <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Figure S2</ext-link>). At a later timepoint, 24 hours, cerebral blood flow within the hypoperfused area of the ipsilateral hemisphere, measured by arterial spin labeling MRI, was 41% (<italic toggle="yes">P</italic>=0.037) and 40% (<italic toggle="yes">P</italic>=0.045) greater in the caADAMTS13- and r-tPA-treated mice, respectively, compared with control (Figure <xref rid="F1" ref-type="fig">1</xref>D and <xref rid="F1" ref-type="fig">1</xref>E). Functionally, r-tPA-, TNK-, and vehicle-treated mice suffered significant neurological deficits 24 hours poststroke compared with their 0-hour baseline score, whereas caADAMTS13-treated mice did not incur this initial deficit (Figure <xref rid="F2" ref-type="fig">2</xref>A). However, between-treatment-group comparisons revealed no significant differences in neurological deficits. A 56% decrease (<italic toggle="yes">P</italic>=0.0003) in the resulting lesion volume compared with the vehicle, quantified at 24 hours by MRI, was observed in the caADAMTS13 treatment group (Figure <xref rid="F2" ref-type="fig">2</xref>B and <xref rid="F2" ref-type="fig">2</xref>C). The spatial extent of bleeds was lower in the caADAMTS13 group compared with r-tPA (Figure <xref rid="F2" ref-type="fig">2</xref>D and <xref rid="F2" ref-type="fig">2</xref>E), with bleed length being independent of lesion volume (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">Table S1</ext-link>).</p><fig position="float" id="F2"><label>Figure 2.</label><caption><p><bold>caADAMTS13 (constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) thrombolysis 1 hour post-acute ischemic stroke prevented behavioral deficits and reduced lesion volume at 24 hours. A</bold>, A 28-point neuroscore test was conducted at baseline (0 hour), 24 hours, and 48 hours poststroke (combined sex, n=21&#x02013;23; male, n=11&#x02013;12; and female, n=10&#x02013;12). <bold>B</bold>, Representative T2-magnetic resonance (MR) images from an animal in each of the treatment groups, 24 hours poststroke. The lesion is visible as the hyperintense area in the right-hand cortex. <bold>C</bold>, Lesion volumes were quantified from the T2-MR images by measuring the area of hyperintensity (combined sex, n=19&#x02013;22; male, n=11; and female, n=9&#x02013;11). <bold>D</bold>, Representative hematoxylin and eosin stained brain sections from an animal in each treatment group, 48 hours poststroke. Error bars are 500 &#x000b5;m for the lower magnification image and 200 &#x000b5;m for the higher magnification insert. Bleeds are visible as the red-stained area and are indicated by the arrow in the insert. <bold>E</bold>, The maximum length of the largest hemorrhage for each mouse was quantified (combined sex, n=19&#x02013;21; male, n=8&#x02013;11; and female, n=9&#x02013;10). Error bars represent mean&#x000b1;SD. Statistics were performed using (<bold>A</bold>) a mixed-effects analysis followed by the Tukey multiple comparisons post hoc test and (<bold>C</bold> and <bold>E</bold>) a Kruskal-Wallis test followed by the Dunn multiple comparisons post hoc test. *<italic toggle="yes">P</italic>&#x0003c;0.05; **<italic toggle="yes">P</italic>&#x0003c;0.01; and ***<italic toggle="yes">P</italic>&#x0003c;0.001. caAD13 indicates caADAMTS13; r-tPA, recombinant tissue-type plasminogen activator; TNK, tenecteplase; and veh, vehicle control.</p></caption><graphic xlink:href="str-56-1589-g002" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>The improvement in reperfusion following caADAMTS13 treatment with respect to the vehicle control reproduces previous results.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Some spontaneous reperfusion occurred in all treatment groups, including with vehicle treatment, which may occur due to variability in the size of the occlusive thrombi formed<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and is comparable to that previously observed.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Between the early (1 hour) and later (24 hours) reperfusion time points, there appeared to be a relative improvement in the r-tPA and TNK groups&#x02019; reperfusion compared with the vehicle and caADAMTS13 treatment groups. This might be expected as caADAMTS13 already had a significant effect on reperfusion within the first hour of treatment; therefore, the incremental change from 1 to 24 hours will be less for the caADAMTS13 group compared with r-tPA and TNK, which show no early reperfusion effect. As proposed elsewhere, this later improvement in cerebral blood flow suggests that r-tPA, and by extension possibly TNK, may be triggering partial reperfusion at a time point between the first and second measurements (1&#x02013;24 hours).<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Nevertheless, while the aim of AIS treatment is to quickly and effectively recanalize and reperfuse occluded blood vessels to prevent irretrievable loss of neuronal tissue and improve stroke outcomes, earlier reperfusion, as observed only with caADAMTS13, tended to display advantages in terms of reducing lesion volume, reducing bleeding events, and reducing initial neurological deficit.</p><p>The success of cerebral reperfusion is dependent on thrombus composition. FeCl<sub>3</sub> dMCAo was used due to its formation of platelet- and VWF-rich, fibrin-poor thrombi<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> that are largely resistant to r-tPA, albeit alongside a slight trend to improvement following r-tPA treatment,<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> consistent with the findings here. r-tPA&#x02019;s variant, TNK, had comparable effects on stroke outcome to r-tPA in our hands, which also holds true for lesion volume in a fibrin-rich dMCAo model.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> As anticipated, caADAMTS13 exhibited improved, or trends to improved, efficacy against platelet- and VWF-rich thrombi, a composition for which there is currently an unmet need for clinical thrombolytics.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> VWF is present in all thrombi to varying proportions<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>; therefore, targeting VWF with caADAMTS13 could additionally be effective against VWF components within platelet-rich and mixed composition thrombi.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Previous studies have investigated means of targeting fibrin and VWF components in parallel, for example, Microlyse, a thrombolytic that localizes plasminogen activation to VWF, with subsequent plasmin cleavage of VWF.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> While caADAMTS13 is suggested to enhance fibrinolysis in vitro,<sup><xref rid="R21" ref-type="bibr">21</xref></sup> this has not been demonstrated in vivo. Future studies should assess caADAMTS13 in fibrin-rich dMCAo, as the potential for a thrombolytic therapy that can act via 2 major thrombus components may significantly increase the pool of patients with AIS for whom thrombolytic therapy may be effective.</p><p>This study has important limitations to consider. Although we found no evidence of sex differences, this study represents the first time that caADAMTS13, and to the best of our knowledge, r-tPA and TNK have been tested as thrombolytics in both sexes in FeCl<sub>3</sub> dMCAo. The absence of observed sex differences in a young, noncomorbid population should not be overinterpreted, and sex differences should continue to be considered alongside comorbidities and additional complexities in models to further enhance translation beyond the scope of the current study.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> While it is argued that neurological deficit can predict the outcomes of patients with AIS, several other behavioral tests could provide greater nuance by assessing specific motor, cognitive, and sensory functions.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Moreover, although this study focused on the acute perfusion effects of the thrombolytics, future studies incorporating behavioral testing over an extended timeframe could provide a better prediction of the functional significance of the early reperfusion achieved by caADAMTS13. Finally, thrombolytic safety assessment by hemorrhage bleed length quantification may not accurately reflect bleeding extent, possibly underestimating or overestimating some bleeds due to 3-dimensional morphology. Currently, all instances of bleeding are considered, but the anterior-posterior distance between brain sections is large in comparison to potential bleed sizes. Sampling sections with higher frequency could enable accurate volumetric quantification of the hemorrhage. In conjunction, implementing a classification system for assessing hemorrhagic transformation characteristics, like those implemented elsewhere,<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> could enhance the qualitative assessment of bleeds, as would employment of T2*-MRI for quantification.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Overall, the results suggest that caADAMTS13 may provide improved early thrombolytic properties compared with the standard of care against platelet- and VWF-rich thrombi in a preclinical stroke model. The early reperfusion achieved by caADAMTS13, rather than later reperfusion also suggested by r-tPA and TNK, led to the trend for a greater extent of improved stroke outcomes of caADAMTS13 over r-tPA and TNK.</p></sec><sec><title>ARTICLE INFORMATION</title><sec><title>Sources of Funding</title><p>This study was supported by the British Heart Foundation 4-Year PhD Studentship Program (grant FS/18/62/34183) to Dr Roberts and The University of Manchester Innovation Factory and a Stroke Association Non-Clinical Lectureship Award to Dr South (grant SA NCL 22100001).</p></sec><sec sec-type="COI-statement"><title>Disclosures</title><p>The Ala1144Val ADAMTS13 variant (caADAMTS13 [constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13]) is the subject of Great Britain (GB) patent application 2102208.2 (A novel biologic for treatment of thrombotic indications), International Patent Cooperation Treaty (PCT) application WO 2022/175666 published on August 25, 2022, Canadian patent application CA3208576 filed on August 25, 2022, European patent application 4294918 filed on December 27, 2023, Chinese patent application 202280015448.3 filed on October 24, 2023, US patent application 18/277,434 filed on February 17, 2022, South Korean patent application 10-2023-7031499 filed on September 14, 2023, Australian patent application 2022223366 filed on September 7, 2023, Singapore patent application 11202306167R filed on February 17, 2022, and Japanese patent application 2023-549646 filed on February 17, 2022.</p></sec><sec><title>Supplemental Material</title><p>Supplemental Methods</p><p>Table S1</p><p>Figures S1&#x02013;S2</p><p>ARRIVE Checklist</p><p>References <xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></p></sec></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Nonstandard Abbreviations and Acronyms</title><def-item><term>ADAMTS13</term><def><p>a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13</p></def></def-item><def-item><term>AIS</term><def><p>acute ischemic stroke</p></def></def-item><def-item><term>caADAMTS13</term><def><p>constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13</p></def></def-item><def-item><term>dMCAo</term><def><p>distal middle cerebral artery occlusion</p></def></def-item><def-item><term>FeCl3</term><def><p>ferric chloride</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>r-tPA</term><def><p>recombinant tissue-type plasminogen activator</p></def></def-item><def-item><term>TNK</term><def><p>tenecteplase</p></def></def-item><def-item><term>VWF</term><def><p>von Willebrand Factor</p></def></def-item></def-list></p></fn></fn-group><fn-group><fn fn-type="equal" id="fn01"><label>*</label><p>K. South and S.M. Allan contributed equally.</p></fn><fn fn-type="financial-disclosure"><p>For Sources of Funding and Disclosures, see page 1594.</p></fn><fn fn-type="supplementary-material"><p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.125.050848</ext-link>.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>LR</given-names></name><name><surname>Adeoye</surname><given-names>O</given-names></name><name><surname>Alemseged</surname><given-names>F</given-names></name><name><surname>Bahr-Hosseini</surname><given-names>M</given-names></name><name><surname>Deljkich</surname><given-names>E</given-names></name><name><surname>Favilla</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Grotta</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>MD</given-names></name><name><surname>Kamel</surname><given-names>H</given-names></name><etal/></person-group>; <collab>XIIth Stroke Treatment Academic Industry Roundtable</collab>. <article-title>Most promising approaches to improve stroke outcomes: the stroke treatment academic industry roundtable Xii workshop.</article-title>
<source>Stroke</source>. <year>2023</year>;<volume>54</volume>:<fpage>3202</fpage>&#x02013;<lpage>3213</lpage>. <comment>doi: 10.1161/STROKEAHA.123.044279</comment><pub-id pub-id-type="pmid">37886850</pub-id>
</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>BCV</given-names></name><name><surname>Mitchell</surname><given-names>PJ</given-names></name><name><surname>Churilov</surname><given-names>L</given-names></name><name><surname>Yassi</surname><given-names>N</given-names></name><name><surname>Kleinig</surname><given-names>TJ</given-names></name><name><surname>Dowling</surname><given-names>RJ</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Bush</surname><given-names>SJ</given-names></name><name><surname>Dewey</surname><given-names>HM</given-names></name><name><surname>Thijs</surname><given-names>V</given-names></name><etal/></person-group>; <collab>EXTEND-IA TNK Investigators</collab>. <article-title>Tenecteplase versus alteplase before thrombectomy for ischemic stroke.</article-title>
<source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>1573</fpage>&#x02013;<lpage>1582</lpage>. <comment>doi: 10.1056/NEJMoa1716405</comment><pub-id pub-id-type="pmid">29694815</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilberto Gonz&#x000e1;lez</surname><given-names>R</given-names></name><name><surname>Furie</surname><given-names>KL</given-names></name><name><surname>Goldmacher</surname><given-names>GV</given-names></name><name><surname>Smith</surname><given-names>WS</given-names></name><name><surname>Kamalian</surname><given-names>S</given-names></name><name><surname>Payabvash</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>GJ</given-names></name><name><surname>Halpern</surname><given-names>EF</given-names></name><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Camargo</surname><given-names>ECS</given-names></name><etal/></person-group>. <article-title>Good outcome rate of 35% in IV-tPA-treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke.</article-title>
<source>Stroke</source>. <year>2013</year>;<volume>44</volume>:<fpage>3109</fpage>&#x02013;<lpage>3113</lpage>.<pub-id pub-id-type="pmid">24003051</pub-id>
</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamowitch</surname><given-names>S</given-names></name><name><surname>Turc</surname><given-names>G</given-names></name><name><surname>Palaiodimou</surname><given-names>L</given-names></name><name><surname>Bivard</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>A</given-names></name><name><surname>De Marchis</surname><given-names>GM</given-names></name><name><surname>Fromm</surname><given-names>A</given-names></name><name><surname>K&#x000f5;rv</surname><given-names>J</given-names></name><name><surname>Roaldsen</surname><given-names>MB</given-names></name><name><surname>Katsanos</surname><given-names>AH</given-names></name><etal/></person-group>. <article-title>European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke.</article-title>
<source>Eur Stroke J</source>. <year>2023</year>;<volume>8</volume>:<fpage>8</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: 10.1177/23969873221150022</comment><pub-id pub-id-type="pmid">37021186</pub-id>
</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keyt</surname><given-names>BA</given-names></name><name><surname>Paoni</surname><given-names>NF</given-names></name><name><surname>Refino</surname><given-names>CJ</given-names></name><name><surname>Berleau</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>J</given-names></name><name><surname>Pe&#x000f1;a</surname><given-names>L</given-names></name><name><surname>Pater</surname><given-names>C</given-names></name><name><surname>Ogez</surname><given-names>J</given-names></name></person-group>. <article-title>A faster-acting and more potent form of tissue plasminogen activator.</article-title>
<source>Proc Natl Acad Sci USA</source>. <year>1994</year>;<volume>91</volume>:<fpage>3670</fpage>&#x02013;<lpage>3674</lpage>. <comment>doi: 10.1073/pnas.91.9.3670</comment><pub-id pub-id-type="pmid">8170967</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kheiri</surname><given-names>B</given-names></name><name><surname>Osman</surname><given-names>M</given-names></name><name><surname>Abdalla</surname><given-names>A</given-names></name><name><surname>Haykal</surname><given-names>T</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Bachuwa</surname><given-names>G</given-names></name><name><surname>Al Qasmi</surname><given-names>M</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name></person-group>. <article-title>Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.</article-title>
<source>J Thromb Thrombolysis</source>. <year>2018</year>;<volume>46</volume>:<fpage>440</fpage>&#x02013;<lpage>450</lpage>. <comment>doi: 10.1007/s11239-018-1721-3</comment><pub-id pub-id-type="pmid">30117036</pub-id>
</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Sui</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>WL</given-names></name><etal/></person-group>. <article-title>Safety and Efficacy of Tenecteplase Versus Alteplase in Patients with Acute Ischaemic Stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.</article-title>
<source>Stroke Vasc Neurol</source>. <year>2022</year>;<volume>7</volume>:<fpage>47</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: 10.1136/svn-2021-000978</comment><pub-id pub-id-type="pmid">34429364</pub-id>
</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cheripelli</surname><given-names>BK</given-names></name><name><surname>Lloyd</surname><given-names>SM</given-names></name><name><surname>Kalladka</surname><given-names>D</given-names></name><name><surname>Moreton</surname><given-names>FC</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name><name><surname>Muir</surname><given-names>KW</given-names></name></person-group>. <article-title>Alteplase Versus Tenecteplase for Thrombolysis After Ischaemic Stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.</article-title>
<source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>:<fpage>368</fpage>&#x02013;<lpage>376</lpage>. <comment>doi: 10.1016/S1474-4422(15)70017-7</comment><pub-id pub-id-type="pmid">25726502</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logallo</surname><given-names>N</given-names></name><name><surname>Novotny</surname><given-names>V</given-names></name><name><surname>Assmus</surname><given-names>J</given-names></name><name><surname>Kvistad</surname><given-names>CE</given-names></name><name><surname>Alteheld</surname><given-names>L</given-names></name><name><surname>R&#x000f8;nning</surname><given-names>OM</given-names></name><name><surname>Thommessen</surname><given-names>B</given-names></name><name><surname>Amthor</surname><given-names>KF</given-names></name><name><surname>Ihle-Hansen</surname><given-names>H</given-names></name><name><surname>Kurz</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Tenecteplase Versus Alteplase for Management of Acute Ischaemic Stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.</article-title>
<source>Lancet Neurol</source>. <year>2017</year>;<volume>16</volume>:<fpage>781</fpage>&#x02013;<lpage>788</lpage>. <comment>doi: 10.1016/S1474-4422(17)30253-3</comment><pub-id pub-id-type="pmid">28780236</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa-Paz</surname><given-names>C</given-names></name><name><surname>P&#x000e9;rez-Mato</surname><given-names>M</given-names></name><name><surname>Bellemain-Sagnard</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Dom&#x000ed;nguez</surname><given-names>M</given-names></name><name><surname>Marie</surname><given-names>P</given-names></name><name><surname>P&#x000e9;rez-Gayol</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez-Arias</surname><given-names>E</given-names></name><name><surname>del Pozo-Fil&#x000ed;u</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez-Amoedo</surname><given-names>S</given-names></name><name><surname>Bugallo-Casal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.</article-title>
<source>J Cereb Blood Flow Metab</source>. <year>2024</year>;<volume>44</volume>:<fpage>1306</fpage>&#x02013;<lpage>1318</lpage>. <comment>doi: 10.1177/0271678X241237427</comment><pub-id pub-id-type="pmid">38436292</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapchak</surname><given-names>PA</given-names></name><name><surname>Araujo</surname><given-names>DM</given-names></name><name><surname>Zivin</surname><given-names>JA</given-names></name></person-group>. <article-title>Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits.</article-title>
<source>Exp Neurol</source>. <year>2004</year>;<volume>185</volume>:<fpage>154</fpage>&#x02013;<lpage>159</lpage>. <comment>doi: 10.1016/j.expneurol.2003.09.009</comment><pub-id pub-id-type="pmid">14697326</pub-id>
</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staessens</surname><given-names>S</given-names></name><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>O</given-names></name><name><surname>Desender</surname><given-names>L</given-names></name><name><surname>Dewaele</surname><given-names>T</given-names></name><name><surname>Vanacker</surname><given-names>P</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>Vanhoorelbeke</surname><given-names>K</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>De Meyer</surname><given-names>SF</given-names></name></person-group>. <article-title>Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance.</article-title>
<source>Haematologica</source>. <year>2020</year>;<volume>105</volume>:<fpage>498</fpage>&#x02013;<lpage>507</lpage>. <comment>doi: 10.3324/haematol.2019.219881</comment><pub-id pub-id-type="pmid">31048352</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Langhauser</surname><given-names>F</given-names></name><name><surname>Desender</surname><given-names>L</given-names></name><name><surname>Vandenbulcke</surname><given-names>A</given-names></name><name><surname>Rottensteiner</surname><given-names>H</given-names></name><name><surname>Plaimauer</surname><given-names>B</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>O</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>Scheiflinger</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice.</article-title>
<source>Blood</source>. <year>2016</year>;<volume>127</volume>:<fpage>2337</fpage>&#x02013;<lpage>2345</lpage>. <comment>doi: 10.1182/blood-2015-08-662650</comment><pub-id pub-id-type="pmid">26929275</pub-id>
</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandelanotte</surname><given-names>S</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>O</given-names></name><name><surname>Desender</surname><given-names>L</given-names></name><name><surname>Staessens</surname><given-names>S</given-names></name><name><surname>Vanhoorne</surname><given-names>A</given-names></name><name><surname>Van Gool</surname><given-names>F</given-names></name><name><surname>Tersteeg</surname><given-names>C</given-names></name><name><surname>Vanhoorelbeke</surname><given-names>K</given-names></name><name><surname>Vanacker</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>r-tPA resistance is specific for platelet-rich stroke thrombi and can be overcome by targeting nonfibrin components.</article-title>
<source>Stroke</source>. <year>2024</year>;<volume>55</volume>:<fpage>1181</fpage>&#x02013;<lpage>1190</lpage>. <comment>doi: 10.1161/STROKEAHA.123.045880</comment><pub-id pub-id-type="pmid">38525646</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinschnitz</surname><given-names>C</given-names></name><name><surname>De Meyer</surname><given-names>SF</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Austinat</surname><given-names>M</given-names></name><name><surname>Vanhoorelbeke</surname><given-names>K</given-names></name><name><surname>Nieswandt</surname><given-names>B</given-names></name><name><surname>Deckmyn</surname><given-names>H</given-names></name><name><surname>Stoll</surname><given-names>G</given-names></name></person-group>. <article-title>Deficiency of von Willebrand Factor protects mice from ischemic stroke.</article-title>
<source>Blood</source>. <year>2009</year>;<volume>113</volume>:<fpage>3600</fpage>&#x02013;<lpage>3603</lpage>. <comment>doi: 10.1182/blood-2008-09-180695</comment><pub-id pub-id-type="pmid">19182208</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B-Q</given-names></name><name><surname>Chauhan</surname><given-names>AK</given-names></name><name><surname>Canault</surname><given-names>M</given-names></name><name><surname>Patten</surname><given-names>IS</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Dockal</surname><given-names>M</given-names></name><name><surname>Scheiflinger</surname><given-names>F</given-names></name><name><surname>Wagner</surname><given-names>DD</given-names></name></person-group>. <article-title>von Willebrand Factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke.</article-title>
<source>Blood</source>. <year>2009</year>;<volume>114</volume>:<fpage>3329</fpage>&#x02013;<lpage>3334</lpage>. <comment>doi: 10.1182/blood-2009-03-213264</comment><pub-id pub-id-type="pmid">19687510</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>K</given-names></name><name><surname>Denorme</surname><given-names>F</given-names></name><name><surname>Salles-Crawley</surname><given-names>II</given-names></name><name><surname>De Meyer</surname><given-names>SF</given-names></name><name><surname>Lane</surname><given-names>DA</given-names></name></person-group>. <article-title>Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.</article-title>
<source>J Thromb Haemost</source>. <year>2018</year>;<volume>16</volume>:<fpage>2289</fpage>&#x02013;<lpage>2299</lpage>. <comment>doi: 10.1111/jth.14275</comment><pub-id pub-id-type="pmid">30152919</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lizarrondo</surname><given-names>SM</given-names></name><name><surname>Gakuba</surname><given-names>C</given-names></name><name><surname>Herbig</surname><given-names>BA</given-names></name><name><surname>Repess&#x000e9;</surname><given-names>Y</given-names></name><name><surname>Ali</surname><given-names>C</given-names></name><name><surname>Denis</surname><given-names>CV</given-names></name><name><surname>Lenting</surname><given-names>PJ</given-names></name><name><surname>Touz&#x000e9;</surname><given-names>E</given-names></name><name><surname>Diamond</surname><given-names>SL</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Potent thrombolytic effect of N-acetylcysteine on arterial thrombi.</article-title>
<source>Circulation</source>. <year>2017</year>;<volume>136</volume>:<fpage>646</fpage>&#x02013;<lpage>660</lpage>. <comment>doi: 10.1161/CIRCULATIONAHA.117.027290</comment><pub-id pub-id-type="pmid">28487393</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Moorsel</surname><given-names>MVA</given-names></name><name><surname>de Maat</surname><given-names>S</given-names></name><name><surname>Vercruysse</surname><given-names>K</given-names></name><name><surname>van Leeuwen</surname><given-names>EM</given-names></name><name><surname>Jacqmarcq</surname><given-names>C</given-names></name><name><surname>Bonnard</surname><given-names>T</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>van der Worp</surname><given-names>HB</given-names></name><name><surname>Dijkhuizen</surname><given-names>R</given-names></name><name><surname>Maas</surname><given-names>C</given-names></name></person-group>. <article-title>VWF-targeted thrombolysis to overcome th-tPA resistance in experimental thrombotic stroke models.</article-title>
<source>Blood</source>. <year>2022</year>;<volume>40</volume>:<fpage>2844</fpage>&#x02013;<lpage>2848</lpage>. <comment>doi: 10.1182/blood.2022016342</comment></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deforche</surname><given-names>L</given-names></name><name><surname>Roose</surname><given-names>E</given-names></name><name><surname>Vandenbulcke</surname><given-names>A</given-names></name><name><surname>Vandeputte</surname><given-names>N</given-names></name><name><surname>Feys</surname><given-names>HB</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name><name><surname>Mi</surname><given-names>LZ</given-names></name><name><surname>Muia</surname><given-names>J</given-names></name><name><surname>Sadler</surname><given-names>JE</given-names></name><name><surname>Soejima</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS13.</article-title>
<source>J Thromb Haemost</source>. <year>2015</year>;<volume>13</volume>:<fpage>2063</fpage>&#x02013;<lpage>2075</lpage>. <comment>doi: 10.1111/jth.13149</comment><pub-id pub-id-type="pmid">26391536</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>K</given-names></name><name><surname>Saleh</surname><given-names>O</given-names></name><name><surname>Lemarchand</surname><given-names>E</given-names></name><name><surname>Coutts</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Schiessl</surname><given-names>I</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name></person-group>. <article-title>Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models.</article-title>
<source>Blood</source>. <year>2022</year>;<volume>139</volume>:<fpage>1575</fpage>&#x02013;<lpage>1587</lpage>. <comment>doi: 10.1182/blood.2021012787</comment><pub-id pub-id-type="pmid">34780600</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>South</surname><given-names>K</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Luka</surname><given-names>N</given-names></name><name><surname>Strangward</surname><given-names>P</given-names></name><name><surname>Coutts</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>CJ</given-names></name><name><surname>Schiessl</surname><given-names>I</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name></person-group>. <article-title>Inhibition of neutrophil rolling and migration by caADAMTS13 in vitro and in mouse models of thrombosis and inflammation.</article-title>
<source>Biomed Pharmacother</source>. <year>2024</year>;<volume>178</volume>:<fpage>117166</fpage>. <comment>doi: 10.1016/j.biopha.2024.117166</comment><pub-id pub-id-type="pmid">39029401</pub-id>
</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Hurst</surname><given-names>V</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Avey</surname><given-names>MT</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.</article-title>
<source>PLoS Biol</source>. <year>2020</year>;<volume>18</volume>:<fpage>e3000410</fpage>. <comment>doi: 10.1371/journal.pbio.3000410</comment><pub-id pub-id-type="pmid">32663219</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatas</surname><given-names>H</given-names></name><name><surname>Evren Erdener</surname><given-names>S</given-names></name><name><surname>Gursoy-Ozdemir</surname><given-names>Y</given-names></name><name><surname>Gurer</surname><given-names>G</given-names></name><name><surname>Soylemezoglu</surname><given-names>F</given-names></name><name><surname>Dunn</surname><given-names>AK</given-names></name><name><surname>Dalkara</surname><given-names>T</given-names></name></person-group>. <article-title>Thrombotic distal middle cerebral artery occlusion produced by topical FeCl3 application: a novel model suitable for intravital microscopy and thrombolysis studies.</article-title>
<source>J Cereb Blood Flow Metab</source>. <year>2011</year>;<volume>31</volume>:<fpage>1452</fpage>&#x02013;<lpage>1460</lpage>. <comment>doi: 10.1038/jcbfm.2011.8</comment><pub-id pub-id-type="pmid">21326267</pub-id>
</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>W</given-names></name><name><surname>Gunion-Rinker</surname><given-names>L</given-names></name><name><surname>Lessov</surname><given-names>N</given-names></name><name><surname>Hazel</surname><given-names>K</given-names></name></person-group>. <article-title>Citicoline treatment for experimental intracerebral hemorrhage in mice.</article-title>
<source>Stroke</source>. <year>1998</year>;<volume>29</volume>:<fpage>2136</fpage>&#x02013;<lpage>2140</lpage>. <comment>doi: 10.1161/01.str.29.10.2136</comment><pub-id pub-id-type="pmid">9756595</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Alfieri</surname><given-names>A</given-names></name><name><surname>Allan</surname><given-names>SM</given-names></name><name><surname>Carswell</surname><given-names>HV</given-names></name><name><surname>Deuchar</surname><given-names>GA</given-names></name><name><surname>Farr</surname><given-names>TD</given-names></name><name><surname>Flecknell</surname><given-names>P</given-names></name><name><surname>Gallagher</surname><given-names>L</given-names></name><name><surname>Gibson</surname><given-names>CL</given-names></name><name><surname>Haley</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>The IMPROVE guidelines (Ischaemia Models: Procedural Refinements of In Vivo Experiments).</article-title>
<source>J Cereb Blood Flow Metab</source>. <year>2017</year>;<volume>37</volume>:<fpage>3488</fpage>&#x02013;<lpage>3517</lpage>. <comment>doi: 10.1177/0271678X17709185</comment><pub-id pub-id-type="pmid">28797196</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Otmani</surname><given-names>H</given-names></name><name><surname>Frunt</surname><given-names>R</given-names></name><name><surname>Smits</surname><given-names>S</given-names></name><name><surname>Barendrecht</surname><given-names>AD</given-names></name><name><surname>de Maat</surname><given-names>S</given-names></name><name><surname>Fijnheer</surname><given-names>R</given-names></name><name><surname>Lenting</surname><given-names>PJ</given-names></name><name><surname>Tersteeg</surname><given-names>C</given-names></name></person-group>. <article-title>Plasmin-cleaved von Willebrand Factor as a biomarker for microvascular thrombosis.</article-title>
<source>Blood</source>. <year>2024</year>;<volume>143</volume>:<fpage>2089</fpage>&#x02013;<lpage>2098</lpage>. <comment>doi: 10.1182/blood.2023021265</comment><pub-id pub-id-type="pmid">38271661</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>SK</given-names></name><name><surname>Lawrence</surname><given-names>CB</given-names></name></person-group>. <article-title>Comorbidity and age in the modelling of stroke: are we still failing to consider the characteristics of stroke patients?</article-title>
<source>BMJ Open Sci</source>. <year>2020</year>;<volume>4</volume>:<fpage>e100013</fpage>. <comment>doi: 10.1136/bmjos-2019-100013</comment></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>A</given-names></name><name><surname>Agin</surname><given-names>V</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Morancho</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>C</given-names></name><name><surname>Koistinaho</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>Schwaninger</surname><given-names>M</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name></person-group>. <article-title>Distal occlusion of the middle cerebral artery in mice: are we ready to assess long-term functional outcome?</article-title>
<source>Transl Stroke Res</source>. <year>2013</year>;<volume>4</volume>:<fpage>297</fpage>&#x02013;<lpage>307</lpage>. <comment>doi: 10.1007/s12975-012-0234-1</comment><pub-id pub-id-type="pmid">24323300</pub-id>
</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orset</surname><given-names>C</given-names></name><name><surname>Arkelius</surname><given-names>K</given-names></name><name><surname>Anfray</surname><given-names>A</given-names></name><name><surname>Warfvinge</surname><given-names>K</given-names></name><name><surname>Vivien</surname><given-names>D</given-names></name><name><surname>Ansar</surname><given-names>S</given-names></name></person-group>. <article-title>Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.</article-title>
<source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>:<fpage>11993</fpage>&#x02013;<lpage>11993</lpage>. <comment>doi: 10.1038/s41598-021-91469-9</comment><pub-id pub-id-type="pmid">34099834</pub-id>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Y&#x000e9;benes</surname><given-names>I</given-names></name><name><surname>Sobrado</surname><given-names>M</given-names></name><name><surname>Zarruk</surname><given-names>JG</given-names></name><name><surname>Castellanos</surname><given-names>M</given-names></name><name><surname>P&#x000e9;rez de la Ossa</surname><given-names>N</given-names></name><name><surname>D&#x000e1;valos</surname><given-names>A</given-names></name><name><surname>Serena</surname><given-names>J</given-names></name><name><surname>Lizasoain</surname><given-names>I</given-names></name><name><surname>Moro</surname><given-names>MA</given-names></name></person-group>. <article-title>A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.</article-title>
<source>Stroke</source>. <year>2011</year>;<volume>42</volume>:<fpage>196</fpage>&#x02013;<lpage>203</lpage>. <comment>doi: 10.1161/STROKEAHA.110.600452</comment><pub-id pub-id-type="pmid">21106952</pub-id>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohene</surname><given-names>Y</given-names></name><name><surname>Harrison</surname><given-names>IF</given-names></name><name><surname>Nahavandi</surname><given-names>P</given-names></name><name><surname>Ismail</surname><given-names>O</given-names></name><name><surname>Bird</surname><given-names>EV</given-names></name><name><surname>Ottersen</surname><given-names>OP</given-names></name><name><surname>Nagelhus</surname><given-names>EA</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Lythgoe</surname><given-names>MF</given-names></name><name><surname>Wells</surname><given-names>JA</given-names></name></person-group>. <article-title>Non-invasive MRI of brain clearance pathways using multiple echo time arterial spin labelling: an Aquaporin-4 study.</article-title>
<source>Neuroimage</source>. <year>2019</year>;<volume>188</volume>:<fpage>515</fpage>&#x02013;<lpage>523</lpage>. <comment>doi: 10.1016/j.neuroimage.2018.12.026</comment><pub-id pub-id-type="pmid">30557661</pub-id>
</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Lythgoe</surname><given-names>MF</given-names></name><name><surname>Van Der Weerd</surname><given-names>L</given-names></name><name><surname>Ordidge</surname><given-names>RJ</given-names></name><name><surname>Gadian</surname><given-names>DG</given-names></name></person-group>. <article-title>Regional variation of cerebral blood flow and arterial transit time in the normal and hypoperfused rat brain measured using continuous arterial spin labeling MRI.</article-title>
<source>J Cereb Blood Flow Metab</source>. <year>2006</year>;<volume>26</volume>:<fpage>274</fpage>&#x02013;<lpage>282</lpage>. <comment>doi: 10.1038/sj.jcbfm.9600185</comment><pub-id pub-id-type="pmid">16034369</pub-id>
</mixed-citation></ref></ref-list></back></article>